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an abnormal angiogenesis is implicated in MMD pathogen-
esis. However, it is unclear whether these anomalies are the 
consequences of the disease or rather causal factors as well 
as these mechanisms remain insufficient to explain the 
pathophysiology of MMD. The presence of a family history in 
about 9–15% of Asian patients, the highly variable incidence 
rate between different ethnic and sex groups and the age of 
onset support the role of genetic factors in MMD pathogen-
esis. However, although some genetic loci have been associ-
ated with MMD, few of them have been replicated in inde-
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 Abstract 
 Background: The pathogenesis of moyamoya disease 
(MMD) is still unknown. The detection of inflammatory mol-
ecules such as cytokines, chemokines and growth factors in 
MMD patients’ biological fluids supports the hypothesis that 
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pendent series. Recently,  RNF213 gene was shown to be 
strongly associated with MMD occurrence with a founder ef-
fect in East Asian patients. However, the mechanisms lead-
ing from  RNF213 mutations to MMD clinical features are still 
unknown.  Summary: The research on pathogenic mecha-
nism of MMD is in its infancy. MMD is probably a complex 
and heterogeneous disorder, including different pheno-
types and genotypes, in which more than a single factor is 
implicated.  Key Message: Since the diagnosis of MMD is rap-
idly increasing worldwide, the development of more effi-
cient stratifying risk systems, including both clinical but also 
biological drivers became imperative to improve our ability 
of predict prognosis and to develop mechanism-tailored in-
terventions.  © 2016 S. Karger AG, Basel 
 Introduction 
 Moyamoya disease (MMD) is a chronic cerebrovascu-
lar disorder characterized by progressive bilateral occlu-
sion of the supraclinoid internal carotid artery (ICA) and 
its main branches, associated with the development of 
fine collateral networks, especially adjacent to the site of 
occlusion in the deep areas of the brain. The appearance 
of the latter on dynamic angiography was originally de-
scribed in the Japanese literature using the expression 
‘moyamoya’, which translates into English as ‘a puff of 
cigarette smoke’  [1, 2] . MMD is a rare disease more fre-
quently occurring in Asian countries, particularly in 
 Japan where an incidence up to 0.54 per 100,000 has been 
reported. However, although MMD has been described 
in all races and ethnicities worldwide, limited data are 
available in Western countries, where the incidence rate 
is probably about 10 times lower (about 0.086 per 
100,000) than in Asia  [3–8] , and it probably remains a 
misdiagnosed cause of ischemic or hemorrhagic stroke 
 [9–12] .
 Cerebrovascular events are the main presenting symp-
toms and are related both to the stenosis and occlusion of 
the ICAs (transient ischemic attack and ischemic stroke) 
and to the rupture of fragile collateral vessels (hemor-
rhagic stroke). Children with MMD usually present with 
ischemic attacks, whereas adults may have either isch-
emic or hemorrhagic events  [13, 14] . Other manifesta-
tions include migraine-like headaches and movement 
disorders. The disease is characterized by individual vari-
ations in the degree of arterial involvement, progression 
of stenosis and response to the reduction of blood supply, 
which would explain the wide range of clinical presenta-
tions. The factors responsible for these different features 
are not well known.
 Recent data support a geographical influence in dis-
ease manifestation. Several studies highlighted the dif-
ferences between MMD presentation in Japanese and 
 American patients. In comparison to Asian cases, Cau-
casian MMD patients are characterized by an older aver-
age age of presentation with lack of bimodal age distri-
bution, prevalence of ischemic stroke type at all ages, 
more benign presenting symptoms and less common fa-
milial occurrence  [7–14] . However, the basis of geo-
graphical differences in disease occurrence and presen-
tation are still unknown, although environmental and 
genetic factors have been invoked as possibly influenc-
ing factors.
 The diagnosis of MMD is made on the basis of certain 
diagnostic criteria  [15, 16] , originally based on cerebral 
catheter angiography. These criteria require the condi-
tion of a bilateral arterial involvement whereas patients 
with unilateral changes, otherwise typical of MMD, are 
classed as ‘probable’ cases, although some of these cases 
develop bilateral changes during follow-up  [17] . In the 
modern era, non-invasive brain MRI and MR angiogra-
phy can show sufficient abnormalities to make the diag-
nosis in many cases, although catheter angiography is still 
required to fully characterize the disease. Disease severity 
has been classified into 6 progressive stages according to 
Suzuki’s classification  [2] . However, this classification is 
purely based on angiographic features and does not take 
into account the clinical phenotype variability. Recently, 
more specific grading criteria, allowing the stratification 
of angiographic severity and clinical symptomatology, 
are being developed for MMD patients, finally aimed at 
assessing clinical symptoms and treatment risks  [18] .
 Angiographic changes otherwise typical of MMD are 
seen also in association with several other diseases or ac-
quired conditions including neck radiotherapy, hormon-
al abnormalities, autoimmune disorders, immunosup-
pressive therapies and infectious diseases as well as ge-
netic disorders including sickle cell disease, protein C and 
S deficiency, Down syndrome and neurofibromatosis 
type 1  [19] . Such cases are often said to have moyamoya 
syndrome (MMS-associated or secondary angiopathy) 
rather than MMD-isolated angiopathy. However, the dis-
tinction is somewhat arbitrary since the obliterative angi-
opathy and collateral formation is often identical in ap-
pearance and consequences (especially in the genetic cas-
es) and the associated conditions are better thought of as 
predisposing conditions rather than causes by them-
selves.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
58
 - 
2/
10
/2
01
7 
12
:3
7:
05
 P
M
 Pathogenesis of MMD Cerebrovasc Dis 2016;41:105–118
DOI: 10.1159/000442298
107
 Nonetheless, the pathogenesis of this enigmatic dis-
ease remains so far unknown, but several hypotheses have 
been investigated. The report of increased levels of in-
flammatory molecules, cytokines, chemokines and 
growth factors in serum and cerebrospinal fluid from pa-
tients with MMD supports the assumption that angio-
genesis anomalies are somehow implicated in disease 
pathogenesis. The association of the MMS with other ge-
netic disorders, the presence of a family history in 9–15% 
of patients with MMD and the identification of a very 
strong association with a variant in the  RNF213 gene in 
East Asian MMD patients support the role of genetic fac-
tors in MMD pathogenesis, although these factors have 
yet to be identified in most patients.
 A possible explanation of the different MMD patho-
physiological characteristics leads to the hypothesis that 
more than one single factor is implicated, leading to the 
consideration of MMD as a multifactorial disease. It is 
believed that MMD is a complex disorder primarily 
caused by multiple gene and angiogenic abnormalities, in 
which unknown triggering environmental factors (in-
cluding infections, immune failure and hemodynamic 
stress to specific vascular loci) seem indispensable for 
starting the first steps of the pathological changes in the 
disease  [20, 21] .
 Herein, we propose an updated review on the patho-
genesis of MMD focusing particularly on angiogenic, vas-
culogenic and genetic aspects.
 Pathophysiological Features of MMD 
 The lack of animal models and of pathological spec-
imens, but also the clinical heterogeneity and the lim-
ited data on disease course particularly in Western 
countries contribute to the incomplete disease knowl-
edge. Research studies, aimed at clarifying the patho-
genic mechanism of the disease, focused on 3 major 
fields: (1) pathological studies of affected tissues, (2) 
studies on the role of vasculogenesis and angiogenesis 
and (3) genetic studies.
 MMD Histopathological Aspects 
 Histopathological studies of MMD-affected ICAs 
demonstrated several particular traits: (1) eccentric fi-
brocellular thickening of the intima, resulting from the 
abnormal proliferation of smooth-muscle-alpha-actin 
positive cells, (2) thinned media, (3) prominently tortu-
ous, often duplicated, internal elastic lamina and (4) ab-
sence of inflammatory or atheromatous involvement 
 [22] . Recent MRI studies have also shown significant 
outer-diameter narrowing of affected vessels, suggesting 
vascular constrictive changes, which were not observed 
in intracranial arterial stenosis caused by atherosclerosis 
 [23, 24] . The abnormal proliferation of intimal cells 
leads to vessel occlusion and thrombosis  [25] with con-
sequent brain hypoxia inducing collateralization through 
the formation of dilated and tortuous perforating arter-
ies. The moyamoya collateral vessels also display a 
thinned media with fibrin deposition in the vessel walls, 
fragmented elastic laminae, attenuated media and mi-
cro-aneurysms, putting these fragile deep vessels at risk 
of rupture  [26] .
 As mentioned before, the particular MMD pathology 
is considered to be responsible for the occurrence of both 
ischemic and hemorrhagic stroke in these patients as at 
histological level, and MMD vessels lack any kind of in-
flammatory characteristics  [27] . Although micro-throm-
bi have been detected in MMD vessels, this finding is not 
specific for MMD and might be interpreted as a result of 
chronic disease rather than the cause  [28] .
 Moreover, MMD has been considered in the majority 
of clinical studies as a typical disease of anterior circula-
tion. Despite this, posterior circulation involvement 
(mainly the posterior cerebral artery) has been mentioned 
since the early 1980s, and it has been repeatedly empha-
sized as one of the most important factors related to poor 
prognosis  [29, 30] . Preliminary data indicate the involve-
ment of some vascular wall progenitor cells in different 
vascular disease states, adding weight to the notion that 
the adventitia is integral to vascular wall pathogenesis 
 [31] . In the contest of progenitor cells, the tunica adven-
titia has emerged as a progenitor-rich compartment with 
niche-like characteristics that support and regulate vas-
cular wall progenitor cells. Due to these findings, more 
efforts should be given from the study of smooth muscle 
cells (SMCs) and pericytes derived from moyamoya-af-
fected middle cerebral and posterior cerebral arteries 
specimens to explain if it is possible to identify a different 
disease origin, linked probably to the different embryo-
logical derivation  [32] .
 Angiogenesis, Extracellular Matrix Remodeling 
 Many research projects have focused on MMD angio-
genesis (sprouting of endothelial cells from existing ves-
sels) and vasculogenesis (formation of new blood vessels 
from circulating bone-marrow-derived endothelial pro-
genitor cells, EPCs), which are probably induced by the 
ischemic and hypoxic phenomena. The involvement of 
an abnormal angiogenesis and vasculogenesis in MMD is 
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sustained by the implementation of fragile collateral 
moyamoya vessels in order to revascularize the distal hy-
poperfused regions.
 Increased expression of angiogenic factors such as 
hypoxia-inducing factor-1α, vascular endothelial growth 
factor (VEGF), basic fibroblast growth factor, granulo-
cyte colony stimulating factor (G-CSF), transforming 
growth factor-β1 (TGFβ1) and hepatocyte growth factor 
was observed both in CSF and serum of MMD patients 
 [33–36] . Significant expression of VEGF was found also 
around the affected vasculature and in glial cells  [36] . 
These findings strongly suggest the existence of intra-
cranial pro-angiogenic environment that may develop 
after the development of proximal cerebral artery steno-
sis. However, although there are no comprehensive in-
vestigations on the mechanistically-related protein 
functions, it seems likely that these factors are involved 
in the native revascularization. Recent studies also 
showed an impaired balance between matrix metallo-
protease (MMPs) and their tissue inhibitors supporting 
the hypothesis that an excessive accumulation of SMCs 
and an abnormal production of extracellular matrix 
(ECM) components may induce vessel stenosis or occlu-
sion  [37, 38] .
 However, the results of these preliminary studies do 
not provide sufficient data to distinguish whether these 
abnormalities are simply a result or, are indeed, causative 
of the disease.
 Endothelial Progenitor and SMC Involvement 
 EPCs are a subset of bone-marrow derived cells, firstly 
isolated and characterized in 1997  [39] that, following en-
dothelial damage, are recruited into systemic circulation 
and are homed to sites of neovascularization through se-
cretion of pro-angiogenic cytokines  [40–42] . Since EPCs 
have been shown to have regenerative and proliferative 
potentials, they were proposed as a potential tool for 
studying human vascular diseases. A reduction of circu-
lating EPCs has been related to endothelial dysfunctions 
in cerebrovascular as well as cardiovascular disease and 
peripheral atherosclerosis  [43–45] . EPCs, from a biologi-
cal point of view, should express at least one marker of 
immaturity and one additional marker reflecting endo-
thelial commitment identified as CD34-, CD133- and 
KDR-positive cell population  [46] .
 EPCs have been investigated to better understand 
and characterize MMD pathogenesis, with controver-
sial results. Jung et al.  [47] firstly reported in a cohort of 
24 adults with MMD: (1) a reduced number of EPCs-
colony forming units, (2) an impairment in EPC func-
tional activity and (3) a higher yield of outgrowth cells. 
These findings were confirmed in MMD children, in 
whom the decreased levels of circulating EPCs, indicat-
ing impaired mobilization and defective function of 
these cells, have been related to the delayed repair of the 
damaged vessel and to the development of vessel occlu-
sion  [48] .
 On the contrary, Yoshihara et al.  [49] demonstrated 
increased levels of CD34-positive cells associated with an 
unusually accelerated neovascularization near the oc-
cluded major cerebral artery in adult patients with angio-
graphic evidence of moyamoya-like vessels. Moreover, 
Rafat et al.  [50] found increased circulating EPCs in 
MMD suggesting that these cells could play a role in im-
proving vasculogenesis and angiogenesis.
 The high level of CD34+ and CD34+CXR4+ circulat-
ing cells in MMD has been associated with the increased 
level of SDF-1α that binds to CXCR4 receptor of CD34+ 
cells and mediates their migration from bone marrow to 
the periphery  [51] .
 The controversial results of preliminary reports could 
be partially explained by differences in analytical meth-
odologies, small sample size and characteristics of popu-
lation studied (age, ethnicity). Further studies are re-
quired to elucidate the functional role of EPCs in MMD 
pathogenesis and to identify the factors by which EPCs 
induced changes and/or recruitment of the compensa-
tory vascular network.
 The potential pathogenic effect of EPCs is further 
highlighted by the ex vivo study by Sugiyama et al.  [52] 
using intracranial artery specimens obtained from 2 
MMD patients. This study provides the first strong indi-
cation that circulating EPCs may be involved in the inti-
mal thickening of the supraclinoid ICA, which is the ini-
tiation site of MMD. In addition, Kang et al.  [53] also 
demonstrated the possibility to differentiate EPCs from 
peripheral blood of MMD patients in smooth muscle pro-
genitor cells (SPCs). The abnormal proliferation of these 
cells is thought to be responsible for the eccentric fibro-
cellular thickening of the intima, which is one of the most 
important MMD histopathological features  [22] . The 
same group demonstrated on tube formation assay that 
SPCs tend to arrange irregularly and form thickened tu-
bules; moreover, they showed an increased expression of 
genes involved in cell adhesion (integrin α3, BAI1-asso-
ciated protein 2-like 1 and N-cadherin), cell migration, 
immune response and vascular development (Eph recep-
tor A5 and MCAM) supporting the idea that these cells 
could provide a further experimental MMD cell model 
 [53] .
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 Genetic Factors in MMD 
 The role of genetic factors in MMD pathogenesis is 
supported by several observations: (1) the highly variable 
incidence rate between different ethnic groups, with a 
marked East–West gradient suggestive of a founder effect 
in East Asian countries, (2) the 9–15% proportion of fa-
milial cases described in the literature, particularly in East 
Asian Countries, (3) the high concordance rate observed 
in monozygotic twins and (4) the drop of mean age of 
onset from 30 years in sporadic cases to 11.8 years in fa-
milial cases.
 Different patterns of inheritance have been suggested. 
Several studies reported pedigrees with parent–offspring 
transmission consistent with an autosomal dominant in-
heritance, most often with an incomplete penetrance 
 [54–56] . Other studies reported pedigrees including only 
affected siblings, suggestive of a possible autosomal reces-
sive transmission  [57–60] . In line with these observa-
tions, a complex determinism with polygenic inheritance 
in most MMD cases and a Mendelian inheritance with 
genetic heterogeneity in some MMD patients have been 
proposed.
 Several molecular genetics studies, mostly conducted 
on Asian MMD patients, have been published since the 
end of the 1990s. They included linkage studies, candi-
date gene association studies and genome-wide associa-
tion studies (GWAS).
 Genome-Wide Linkage Studies 
 A number of linkage studies has been conducted and 
are listed in  table 1 . Five main loci were linked to MMD 
(3p24.2p26, 6q25, 8q23, 12p12 and 17q25). Except for the 
17q25 locus, none of these loci has been replicated in in-
dependent series. Yamauchi et al.  [59] firstly identified a 
linkage to the 17q25 locus. This result was later replicated 
in several whole genome linkage analyses conducted on 
multigenerational families, allowing the progressive re-
duction of the candidate interval to a 1.5 Mb region on 
17q25.3  [55, 56, 61] .
 Candidate Gene Association Studies 
 Many candidate gene association studies have been 
performed, based on various pathophysiological hy-
potheses. The first association studies investigated the 
role of human leukocyte antigens (HLAs), located on 
chromosome 6p21.3. In 1995, Aoyagi et al.  [62] showed 
a significant association between HLA B51 and HLA 
B51-DR4 combination in Japanese MMD patients. In-
oue et al.  [63] genotyped HLA gene alleles in 71 Japa-
nese and 525 control subjects in 1997 and also detected 
a positive association for DQB1 * 0502. Han et al.  [64] 
studied 28 Korean patients and 198 controls and report-
ed an association of MMD with HLA B35. These results 
were not confirmed by Hong et al.  [65] who did not find 
any difference in HLA genotype between MMD and 
controls, except for an association between familial 
MMD (fMMD) and DRB1 * 1302 and DQB1 * 0609 al-
leles. More recently, Kraemer et al.  [66] found that Eu-
ropean patients with moyamoya angiopathy (including 
unilateral cases) carried more frequently than controls 
HLA DRB1 * 03, DRB1 * 13, A * 02, B * 08 and DQB1 * 03 
antigens. However, the limited sample size of most 
studies and the lack of results replication make their in-
terpretation quite difficult.
 Based on the observation of an increased expression of 
pro-angiogenic and growth factors in patients’ CSF, blood 
or tissues compared to controls, variations in the coding 
sequences and promoters of genes encoding for pro-an-
giogenic factors have been screened  [67–73] . Some of 
these studies found associations between MMD and poly-
morphisms in growth factor genes such as platelet-de-
rived growth factor receptor beta or TGFβ1, but replica-
tion was missing.
 MMPs and metalloprotease tissue inhibitor path-
ways (TIMPs), which are known to regulate the interac-
tion between SMCs and ECM, have also been investi-
gated in MMD  [74] . In line with the observation of a 
differential expression of these ECM remodeling en-
zymes between patients’ and controls’ biological sam-
ples, some studies showed an association of MMD with 
polymorphisms located in of TIMP2, MMP2, MMP3 
genes or in their promoters  [75–78] . Again, conflicting 
results between studies did not allow any conclusions to 
be drawn about the significance of these associations 
 [73, 79, 80] .
 Results of candidate gene studies are listed in  table 2 .
 GWAS 
 In 2011, Kamada et al.  [81] performed a GWAS study 
including 72 Japanese MMD patients and 45 healthy 
 Japanese controls, showing an association between MMD 
and a single locus on 17q25-ter (p  < 10 –8 ). They con-
firmed this result in a locus-specific association study, 
showing a strong association between MMD and 20 SNPs 
spanning a 151 kb region within the RNF213 locus (p < 
10 –6 ). The study also showed a very strong association 
with MMD of a single haplotype including 7 SNPs locat-
ed in the 3 ′ UTR of RNF213 (p = 5.3 × 10 –10 ) supporting 
evidence for a founder effect in the Japanese population 
 [81] .
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at
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 p
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m
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 C
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r f
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ra
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 m
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 c
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 m
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 p
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 o
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 m
ar
ke
rs
In
 e
ac
h 
af
fe
ct
ed
 si
bl
in
g 
pa
ir
, 
es
tim
at
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 m
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r l
oc
at
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m
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at
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 p
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 m
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 d
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 d
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 re
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 m
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t l
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 m
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 c
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t m
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ra
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m
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m
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m
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 p
at
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s m
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 C
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l m
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 p
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ra
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lin
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 re
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 p
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 p
at
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M
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ra
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at
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 C
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 m
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 d
om
in
an
t m
od
el
 
ta
ki
ng
 in
to
 a
cc
ou
nt
 a
 p
os
si
bl
e 
lo
cu
s h
et
er
og
en
ei
ty
 (H
LO
D
)
A
ffe
ct
ed
 m
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 p
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s c
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at
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 m
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 c
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 c
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 c
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at
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 m
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 re
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 m
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 c
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) c
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 c
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 d
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 m
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 m
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l f
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 c
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 m
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t m
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 c
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 p
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 c
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 m
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at
io
n 
an
al
ys
is
 
us
ed
 fo
r i
nt
er
pr
et
at
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m
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 c
an
di
da
te
 re
gi
on
 o
f 1
.5
 M
b 
on
 
17
q2
5.
3 
co
nt
ai
ni
ng
 2
1 
ge
ne
s
– 
 Se
gr
eg
at
io
n 
of
 a
 sh
ar
ed
 d
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 d
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 p
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f o
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 c
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 In 2013, a GWAS conducted in Caucasians, including 
38 unrelated German and Czech patients and 41 German 
controls, suggested possible associations with 7 SNPs (lo-
cated on 1q23.3, 2p22.1, 13q14.11, 17p13.3, 20q13.33, 
3p22.1 and 4q22.3; p < 10 –5 ) but failed to identify a sig-
nificant association with MMD. Direct sequencing in 5 
patients of 8 genes included in these candidate regions 
revealed 79 variants including 5 missense variants, com-
monly found in Caucasian control population, making 
them unlikely to be responsible for MMD. No association 
with  RNF213 polymorphism was found in Caucasian pa-
tients  [82] ( table 2 ).
 RNF 213 and MMD 
 Following the identification of the association be-
tween MMD and RNF213, a second Japanese research 
team established linkage to the  RNF213 locus at 17q25.3 
in 8 multigenerational MMD families and identified, by 
whole exome sequencing, RNF213 as a major candidate 
gene for MMD  [56] . Mutational analysis followed by 
case–control association studies revealed a strong asso-
ciation between MMD in East Asian countries and a sin-
gle missense mutation in  RNF213 (p.R4810K, also des-
ignated as p.R4859K according to the NM transcript 
considered), leading to an aminoacid substitution from 
Arginine to Lysine in the C-terminal part of the protein. 
This mutation was found in 90% of Japanese, 79% of 
Korean and 23% of Chinese MMD cases and strongly 
increased the risk to develop MMD with an OR 338.9 
(p = 10 –100 ) in Japanese, OR 135.6 (p = 10 –25 ) in Korean 
and OR 14.7 (p = 10 S4 ) in  Chinese populations  [56] . Fur-
ther independent studies confirmed this association in 
Japanese patients. Miyatake et al.  [83] showed the pres-
ence of this mutated allele in 95.1% of fMMD cases and 
79.2% of sporadic MMD cases, with an OR 259 (p  < 
0.001).
 Miyawaki et al.  [83] found the mutated allele in 85.4% 
of MMD patients (OR 292.8, p < 0.0001) and in 21.9% in 
non-MMD intracranial major artery stenosis occlusion 
(OR 14.9, p = 0.01). This association was also replicated 
in Chinese Han patients, although at a lower level, with 
the presence of p.R4810K variant in 13% of MMD Han 
patients (OR 36.7, p = 6 × 10 –15 )  [85] . Of note, in these 
studies, the p.R4810K variant was found in 1–2% of 
 Japanese controls and in 0.4% of Chinese Han controls, 
and therefore, it should be considered as a MMD suscep-
tibility variant rather than a MMD causing variant. It was 
also suggested that presence of the p.R4810K variant, 
when present in an homozygous state, was associated 
with an earlier onset and a more severe disease course, 
suggesting a value of this variant as a biomarker for pre-
dicting prognosis  [83, 86, 87] .
 If the role of p.R4810K variant in  RNF213 gene as a 
susceptibility variant for MMD is clear in East Asian sub-
jects, neither this variant nor the founder haplotype have 
been detected in Caucasian patients  [81, 82, 88] . A recent 
study, conducted in the United States, showed the pres-
ence of p.R4810K in 56% of unrelated MMD of Asian de-
scent (Korean, Japanese and Chinese but also Indian and 
Bangladeshi ethnicities) whereas it was not identified in 
European or Hispanic Americans. Analysis of familial 
cases showed co-segregation of p.R4810K with the MMD 
phenotype, but with an incomplete penetrance  [88] .
 Some additional  RNF213 rare variants were identified 
in Asian and Caucasian MMD patients negative for p.
R4810K  [56, 81, 88] . These variants were mostly missense 
variants except 3 molecular variants reported by Cecchi 
et al.  [88] , which consisted of 1 in-frame insertion and 2 
small in-frame deletions. Except for 1 missense variant 
(p.D4013N) detected in 2 unrelated Caucasian patients 
from 2 distinct studies, all variants were private. Interest-
ingly, p.R4810K variants and almost all additional vari-
ants were located in the C-terminus part of the RNF213 
protein.
 The exact mechanism by which the RNF213 would be 
involved in MMD pathogenesis remains unknown. 
RNF213 encodes for a large cytosolic protein ubiquitous-
ly expressed, and containing a ring-finger domain (sug-
gestive of an E3 ubiquitin ligase domain) and an AAA-
ATPase domain. In-vitro functional studies showed that 
the p.R4810K variant did not alter stability, intracellular 
distribution or ubiquitin activities  [56] . Zebrafish knock-
down for RNF213 was reported to have severely abnor-
mal sprouting vessels in the head region, especially from 
the optic vessels  [56] .
 Genetically engineered mice that lack  RNF213 do not 
exhibit abnormalities in brain vasculature under physio-
logical conditions  [89, 90] . However, after carotid artery 
ligation, knockout mice did not present the transitory in-
timal and medial hyperplasia found in their wild-type lit-
termates and had significantly thinner intimal and me-
dial layers than wild type mice, suggesting a possible role 
of  RNF213 in arterial wall remodeling  [91] . Finally, recent 
experimental studies performed on p.R4810K-mutated 
cells showed a reduced angiogenic activity, and in anoth-
er study, cycle cell perturbation with increased genomic 
stability  [92, 93] .
 However, the exact mechanism by which RNF213 mo-
lecular variant lead to MMD clinical features is still un-
known.
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 Discussion 
 The pathophysiological mechanisms of MMD remain 
poorly understood. Although, the results from experi-
mental studies conducted so far highlight the presence of 
abnormalities in angiogenic pathway and cellular prolif-
erative signaling cascade at the base of both native revas-
cularization and vessel stenosis or occlusion, these find-
ings are still inadequate to fully explain MMD biological 
mechanisms.
 Several elements, including the different incidence 
rate between ethnicities and the high rate of familial oc-
currences, support the role of genetic factors in MMD. A 
very strong association between MMD and a missense 
variant in RNF213 (p.R4810K) has been reported by sev-
eral studies in East Asian patients. This variant, which is 
present in 1–2% of the Japanese control population, was 
found in more than 90% of MMD patients  [82, 83, 87, 
88] . However, although this variant has been established 
as a susceptibility factor for MMD in East Asia, it may 
explain only part of the disease susceptibility in this pop-
ulation and it is probably not involved in Caucasian pa-
tients.
 However, the identification of the additional genes 
that are most likely involved in MMD was hampered by 
several factors, including (1) the complex pattern of in-
heritance and genetic heterogeneity of MMD, (2) the lim-
ited samples size used so far to map and identify those 
genes, (3) the fact that investigated gene or SNPs might 
not have a causative effect on the pathogenesis of MMD 
(might rather only be related to some disease aspect) and 
(4) the genetic methodology, that in most cases was the 
candidate gene approach, limiting the number of ex-
plored polymorphisms in any study whereas, probably, 
many common genetic variants contribute to the risk of 
MMD.
 The results of the available studies, as well as our clin-
ical and research experience in MMD, support the idea 
that probably one single mechanism is unable to explain 
the complex disease pathogenesis. MMD angiopathy is 
a heterogeneous, multifaceted disease in which, proba-
bly, different pathogenic processes contribute to the dis-
ease onset and progression  [94] . According to this con-
cept, an intriguing hypothesis, the so-called ‘double-hit 
mechanism’ has been proposed, supported by the asso-
ciation between MMD angiopathy and several acquired 
and genetic conditions, including definite entities such 
as sickle cell disease, protein C and S deficiency, Down 
syndrome and neurofibromatosis type 1 as well as the 
recently identified  RNF213 mutations in East Asians. 
MMD could result from a set of linked and subsequent 
events in which environmental factors may influence 
the development of arteriopathy in genetically suscep-
tible individuals. In particular, it has been supposed that 
in specific genetic and acquired conditions, several fac-
tors such as infectious agents, immunological responses 
but mostly an overlapping insult of endothelium attrib-
uted to flow dynamics such as shear stress, which may 
be related to SMC migration at internal carotid termi-
nal, may trigger to ICA stenosis  [19] . The involvement 
of epigenetic factors may also explain the extreme vari-
ability in clinical phenotype, in progression rate and 
disease susceptibility in East Asians and Caucasians 
 [95] .
 Ultimately, the impression is that our understanding 
of the disease is not assisted by the variability of disease 
phenotype and the arbitrary diagnostic criteria applied so 
far, including uncertainty whether to distinguish between 
disease or syndrome, or consider the overall MMD angi-
opathy. The application of the available diagnostic crite-
ria, although appealing for clinical management, may 
provide poor reliable and confounding subgroups clas-
sification that may finally hamper the identification of 
definite phenotypes. Moreover, although the impact of 
ethnicity is becoming increasing important, the risk strat-
ification by ethnicity is still not defined due to the lack of 
data on European population  [96] .
 Since the diagnosis of MMD is rapidly increasing 
worldwide, these considerations support the need for de-
veloping more specific and efficient stratifying risk sys-
tems, including deep clinical and radiological phenotyp-
ing but also the identification of disease biomarkers 
through genomic and metabolomic studies  [95] . The 
identification of at-risk phenotypes and/or specific bio-
logical drivers could improve our ability to predict prog-
nosis and to develop individually tailored interventions 
 [95] .
 The extensive application of high-throughput tech-
nologies, such as GWASs, or novel sequencing technolo-
gies, such as next generation sequencing, may help to 
overcome limitations of previous genetic investigations, 
mostly in familial cases. However, given the disease com-
plexity, an integrated approach including advanced ge-
nomic technologies, biochemical and functional studies 
but also a strong clinical approach, including detailed 
phenotyping in order to identify clinically homogeneous 
subgroups of patients and collaborative efforts to collect 
large MMD patients series and DNA samples seem to be 
the best strategy to maximize our understanding of the 
mysteries of MMD pathogenesis.
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